In this edition, the importance of vaccination after cell therapy, artificial intelligence may help predict cardiotoxicity, experimental breast cancer vaccine generates immune response, and more. Read the full coverage here: Revaccination guidance after cell therapy established for some, 'evolving' for others Artificial intelligence may help predict cardiotoxicity in renal cell carcinoma Experimental breast cancer vaccine generates immune response to key tumor protein Cancer cell therapy for melanoma has potential to save 'thousands' of lives each year CAR-T regimen 'should be new standard' for high-risk B-cell acute lymphoblastic leukemia References: Disis ML, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5143. Sarnaik A, et al. Abstract 789. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston. Saullo JL, et al. The importance of re-vaccination after cellular therapy. Presented at: NCCN 2022 Annual Congress: Hematologic Malignancies; Oct. 14-15, 2022; New York. Wang T, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.01214 Yasin H, et al. Abstract 16. Presented at: International Kidney Cancer Symposium: North America; Nov. 4-5, 2022; Austin, Texas.

Ver todos los episodios